Variantyx, a Framingham, MA-based company which specializes in genomic precision medicine, raised an additional funding of undisclosed amount.
The round saw participation from Robert Bosch Venture Capital, Pitango HealthTech, New Era Capital Partners, 20/20 HealthCare Partners and Peregrine Ventures.
The company intends to use the funds, which brought the total amount to over $120m, to accelerate its commercial expansion.
Led by CEO Haim Neerman, Variantyx is a technology-driven precision medicine company providing solutions for the genetic disorders, reproductive health, and precision oncology markets. Its proprietary whole genome analysis platforms allow clinicians and patients to understand a person’s genetic makeup, diagnostic capabilities and improved personalized treatment recommendations.
FinSMEs
19/10/2023